Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1117923 | 1.00 | CA2 (0.53) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL6980879 | 0.95 | CA2 (0.53) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL1044755 | 0.95 | CA2 (0.53) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL10832816 | 0.90 | CA2 (0.51) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL8123526 | 0.88 | CA2 (0.49) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL438614 | 0.88 | CA2 (0.49) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL11102654 | 0.87 | LMNA (0.48) | CA2LMNAFFAR1SMN1; SMN2CYP2C9 | |
| SCHEMBL9369808 | 0.86 | CA2 (0.53) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL6629428 | 0.86 | CA2 (0.53) | CA2CA1LMNAFFAR1SMN1; SMN2 | |
| SCHEMBL6973466 | 0.85 | CA2 (0.57) | CA2LMNAFFAR1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009120192-A2 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JASSEN PHARMACEUTICA, N.V. (BE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120191-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES AND CRYSTALLINE FORM OF N- ( ( (2S) -6-CHLORO-2,3-DIHYDRO-L,4-BENZODIOXIN-2-YL) METHYL-SULFAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JANSSEN PHARMACEUTICA, N.C. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JANSSEN PHARMACEUTICA, N.C. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247617-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247617-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | CYP3A4, CYP3A5, CYP1A2 | CA2 3270/4885CA1 2909/4885LMNA 1717/4885 |
| US-20090247617-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES | STS, SULT2A1, GABRE | CA2 2134/4885CA1 1020/4885LMNA 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.